Dr. Pedro Barata of University Hospitals Seidman Cancer Center and Dr. Ugwuji Maduekwe of the Medical College of Wisconsin discuss the emergence of organ preservation in GEJ and gastric cancers on the latest episode of the ASCO Education #BytheBook Podcast. Listen here: https://bit.ly/4tAUje4

JCO Global Oncology (JCO GO) guest editors Drs. Fabio Ynoe de Moraes & Paul Pearlman discuss JCO GO's Special Series featuring the investigators working to develop a new generation of innovations through the NCI’s Affordable Cancer Technologies Program. Read more: https://bit.ly/4tr3vl9

The draft guideline update for "Breast Cancer Follow-Up After Primary Treatment" is now available. Help us refine these standards of care. Submit your feedback to @ascocancer.bsky.social by February 23! Read & comment here: https://bit.ly/4ccwl2h #bcsm #BreastCancer

Big news! Onyinye D. Balogun, MD, MSc joins JCO Global Oncology as the new Associate Editor! We’re excited to have her expertise from @northwellhealth.bsky.social. Welcome, Dr. Balogun! #JCOGO #GlobalOncology

We are thrilled to announce that Dr. Chiara Cremolini is joining the Journal of Clinical Oncology (JCO) as our newest Associate Editor! Her expertise in colorectal oncology & clinical and translational research aligns perfectly with our mission to advance cancer care.

New #ASCO #JCO Cancer Stories: "A Chance to Heal with Cold Hard Steel" with host @mikkaelsekeres.bsky.social#ASCO#JCODr. Taylor Goodstein shares a powerful perspective on surgery, grief, and finding courage within our own fallibility. Tune in: https://bit.ly/4rG0nQL

JCO Updated Stage IV NSCLC guidelines: ➡️ASCO Living Guideline: Stage IV NSCLC (With Drivers) https://bit.ly/49SWlye ➡️ASCO Living Guideline: Stage IV NSCLC (Without Drivers) https://bit.ly/4at28L1

Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology. Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide. Join us in congratulating Dr. Moraes! #GlobalOncology

#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel. Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts? A: Largely, no! Similar communication, slight ⬆️ appts. ascopubs.org/doi/full/10....

We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!

In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social#JCO Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children. Listen here: https://bit.ly/3ZxVYD9 #ArtOfOncology

When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity. Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...

New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status. Stay current on mCRPC care: brnw.ch/21wZfuI

Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0

Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology. ascopubs.org/doi/10.1200/...

Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team. Get tips on peer review & publishing your manuscript. Limited space—first come, first served! 📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005

Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations. Learn more: brnw.ch/21wYSoe

Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions. Read the full article. ascopubs.org/doi/abs/10.1...

Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing. Read the full article. ascopubs.org/doi/abs/10.1... #BreastCancer #bcsm

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social. In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent. 🎧: ascopubs.org/do/smell-sce...

Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer. 👉 See the analysis: ascopubs.org/doi/abs/10.1... #BreastCancer

🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See the results: ascopubs.org/doi/abs/10.1... #HER2Positive #BreastCancer

🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies. Listen here: ascopubs.org/do/milan-con...

New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care! Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane. 👉 Read the results: ascopubs.org/doi/abs/10.1... #TNBC #BreastCancer

🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this! Learn more: ascopubs.org/doi/abs/10.1... #CLL #SLL

“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.” In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr

The first-ever Phase III randomized showdown is here! See results of pirtobrutinib vs. ibrutinib in treatment-naïve and R/R patients. Is the non-covalent BTKi the game-changer we’ve waited for? #ASH25 simultaneous publication with Woyach et al. is LIVE: brnw.ch/21wYbdz

The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care. 👉 Read the full abstract: brnw.ch/21wYb73 #ALamyloidosis #Hematology

Pennsylvania Farmers & Skin Health: Unpacking the link between specific agricultural practices and melanoma incidence in the Keystone State. Learn more: brnw.ch/21wXMUK

"I was lucky. I had good insurance, I lived in LA, I was treated at 4 big cancer centers.   I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist." 🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:

Check out #JCOGO's new article, discussing implementation of geriatric assessment in resource-constrained settings and some outstanding implementation questions and concerns. Learn more: brnw.ch/21wXieA

Check out the article in JCO on the Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Learn about the latest research on this common drug's potential role in managing prostate cancer: brnw.ch/21wX6DG

Publish with JCO GO or JCO OA. Advantages of fully #OpenAccess journals include: More citations & downloads Greater engagement A wider opportunity to advance cancer care globally Compliance with funder mandates With International #OAWeek coming up, learn how you can expand your reach.

Listen to the latest @ascocancer.bsky.social #JCO Cancer Stories: The Art of Oncology episode "A Fight Bigger Than Myeloma” with host Dr. Mikkael Sekeres & Dr. Adeel Khan who uses pt's multiple myeloma story to highlight civil liberties progress & the work still ahead. 🎧: brnw.ch/21wWO0S #mmsm

We encourage all AI submissions, but JCO will prioritize studies that demonstrate clinical impact. Read more in our guide: Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at JCO: A Guide for Studies Testing Artificial Intelligence Models: brnw.ch/21wWuAG

Meet the dedicated leaders of our journals! Introducing the Editors-in-Chief for JCO Clinical Cancer Informatics, JCO Precision Oncology, and JCO Oncology Advances. They deliver authoritative, peer-reviewed content that is shaping the future of cancer research.

Meet our Editors-in-Chief! These leaders guide JCO, JCO Oncology Practice, and JCO Global Oncology to ensure you get the most credible, authoritative, and peer-reviewed oncology content. Their mission: informing high-quality patient care across the globe.

Check out #JCOGO's article "Understanding Barriers to Clinical Cancer Research in the Asia-Pacific." ➡️ brnw.ch/21wW8fC

💡Check out this IAEA update on radiotherapy resources in Central Asia. ascopubs.org/doi/10.1200/... @jco-asco.bsky.social @iaeaorg.bsky.social

Terrific (&entertaining) piece by @jco-asco.bsky.social OP editor @ethicsdoctorp.bsky.social on what he thinks AI could do to transform oncology practice by 2035. OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice ascopubs.org/doi/full/10....

We're thrilled to be here on BlueSky to bring you the latest practice-changing oncology research from all six JCO Journals! Follow-us for great content from #JCO, #JCOOP, #JCOGO, #JCOPO, #JCOCCI, & #JCOOA.